Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
June 24, 2026 | AI, HEOR, Market Access, RWE, evidence, evidence synthesis, genesis, literature reviews, slr
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers.
Developed in-house by Genesis scientists and refined through two years of real-world application in client evidence work, EVID AI provides a structured environment for conducting evidence synthesis activities, from rapid evidence queries and targeted literature reviews to ongoing literature surveillance and end-to-end systematic reviews.
Designed as a flexible working model, the EVID AI free access program enables teams and individuals to run projects independently, collaborate with Genesis experts, or delegate entirely, depending on their needs.
“Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
A single environment for evidence work
EVID AI brings evidence activities into one place, removing fragmentation across tools and processes, providing teams with a practical way to apply the same structured approaches used in evidence work within a single platform and workflow. It enables teams to:
- Identify and assess relevant literature
- Manage structured review workflows
- Monitor evolving evidence landscapes
- Support decision-making with clearer, more structured outputs
Designed for life sciences decision-making
EVID AI has been built and refined within Genesis’ own work, reflecting evidence synthesis needs across HEOR, RWE, Medical Affairs, and Market Access.
By aligning with real-world workflows, it supports faster, more informed decisions across the product lifecycle, supporting how therapies are evaluated, understood, and ultimately made available to patients.
Access and next steps
Approved users will receive free platform access through 31 December 2026, with optional access to Genesis expertise for protocol design, search strategy, screening, interpretation, and full project delivery.
Expert support remains separate from the platform offer and is provided based on user needs. Interested individuals can request access via the Genesis website.
Request free access at genesisrg.com.
About Genesis Research Group
EVIDENCE. EXPERIENCE. JUDGMENT.
Genesis Research Group is a global life sciences consulting firm specializing in evidence generation, health economics and outcomes research, real-world evidence, market access, pricing strategy, and stakeholder insights. Genesis combines rigorous evidence, deep expertise, and practical judgment to help companies reduce uncertainty and make better decisions across development, launch, access, and commercialization.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group’s recent expansion of its real-world data…
Genesis Research Group announces inaugural membership of ISPOR Corporate Partnership Program
Genesis Research Group, a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, today announces it has joined selected organizations as an inaugural…
Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act
To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to…
Genesis Research Group ISPOR Europe presentation ‘Planning with Insights: Even the Best Economic Models Need Validation’ features in scientific publication
We are pleased to share that The Evidence Base have carried out a ‘deep dive’ into a Genesis Research Group presentation on economic modeling in healthcare and harnessing stakeholder insights…
Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
Genesis Research Group’s poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey’ was recently named as…
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition…
Genesis Research Group unveils enhanced US market access data analytics
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities…
Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers
Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.
Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program
Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life…
Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’
ITN Business invited Genesis Research Group to contribute to a news style programme ‘Advancing Healthcare’ featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one…